This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is a Beat Likely for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
AbbVie's (ABBV) second-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on any update related to guidance.
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, PFE, ABBV, LLY & MRK FDA Updates
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.
Roche's (RHHBY) 1H21 Sales Rise Despite Impact of Biosimilars
by Zacks Equity Research
Roche's (RHHBY) performance in first-half 2021 was impressive on strong demand for new medicines and COVID-19 test kits. Impact of biosimilars continues to hurt sales.
Biogen (BIIB) Q2 Earnings Top, Aduhelm Early Sales Hit $2M
by Zacks Equity Research
Biogen (BIIB) beats second-quarter estimates for both earnings and sales and ups sales guidance for 2021.
AbbVie (ABBV) Venclexta Gets Breakthrough Therapy Tag for MDS
by Zacks Equity Research
The FDA grants a Breakthrough Therapy designation to AbbVie's (ABBV) Venclexta in combination with azacitidine for treating adult patients with higher risk myelodysplastic syndrome.
Regeneron's (REGN) Antibody Cocktail for COVID-19 Approved in Japan
by Zacks Equity Research
Regeneron's(REGN) cocktail for the treatment of COVID-19 gets approval in Japan as Ronapreve.
Bayer's (BAYRY) Parkinson's Disease Therapy Gets Fast Track Tag
by Zacks Equity Research
The FDA grants a Fast Track status to Bayer's (BAYRY) DA01 cell therapy which is being developed for the treatment of Parkinson's disease.
Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on commercialization plans for new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports second-quarter earnings.
Bristol Myers' (BMY) Opdivo+Yervoy Fails First-Line SCCHN Study
by Zacks Equity Research
Bristol Myers' (BMY) late-stage study evaluating Opdivo in combination with Yervoy as a first-line treatment for squamous cell carcinoma of the head and neck fails to meet goal.
BioMarin (BMRN) Gets EMA Validation for Hemophilia Gene Therapy
by Zacks Equity Research
The EMA validates BioMarin's (BMRN) marketing application for valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
Lilly's (LLY) Protomer Acquisition to Expand Diabetes Pipeline
by Zacks Equity Research
Lilly (LLY), which holds a 14% stake in private biotech company Protomer, acquires the remaining interest in it. The acquisition is set to expand Lilly's diabetes pipeline.
J&J (JNJ) Recalls Some Sunscreens Due to Benzene Presence
by Zacks Equity Research
J&J (JNJ) withdraws five aerosol sunscreen products from the market due to "low levels" of benzene found in some samples.
AstraZeneca (AZN) Gets Clearance in UK for Alexion Acquisition
by Zacks Equity Research
AstraZeneca (AZN) obtains UK Competition and Markets Authority's permission for the impending acquisition of Alexion. The deal is expected to close on Jul 21, 2021.
Celldex (CLDX) Up Almost 40% Since Skin Disorder Study Data
by Zacks Equity Research
Celldex (CLDX) announces 95% response rate in urticaria patients in an early-stage study evaluating a single dose of its antibody candidate, CDX-0159. Shares are up almost 40% since last Friday.
Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk
by Zacks Equity Research
Prothena (PRTA) announces an agreement to sell its clinical-stage antibody, PRX004, and the broader ATTR amyloidosis program for $1.2 billion to Novo Nordisk.
AbbVie (ABBV) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Sigilon (SGTX) Down as FDA Places Hold on Hemophilia Study
by Zacks Equity Research
Sigilon (SGTX) stock declines as the FDA puts a clinical hold on its early/mid-stage hemophilia A study that was evaluating its lead candidate SIG-001.
Biogen (BIIB) Gets FDA Nod for Narrow Label of Aduhelm
by Zacks Equity Research
The FDA approves label update for Biogen's (BIIB) new Alzheimer's drug, Aduhelm. The updated label narrows the patient population, which is eligible for the drug.
WHO Guidelines Put Spotlight on Arthritis Drugs Actemra & Kevzara
by Zacks Equity Research
The latest guideline update by the WHO includes the use of arthritis drugs like Roche's (RHHBY) Actemra and Sanofi's (SNY) Kevzara for the treatment of severe COVID-19.
3 Reasons to Invest in Regeneron Pharmaceuticals (REGN) Now
by Zacks Equity Research
Regeneron's (REGN) efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive and makes it a good bet for investors, for now.
Merck (MRK) to Withdraw a Gastric Cancer Indication for Keytruda
by Zacks Equity Research
Merck's (MRK) Keytruda is approved under FDA's accelerated pathway for recurrent gastric or gastroesophageal junction adenocarcinoma indication but fails in post-marketing commitment study.
Pharma Stock Roundup: EU Nod to RHHBY, MRK Drugs, FDA and Pipeline Updates
by Kinjel Shah
EU approves Roche's (RHHBY) Enspryng and Merck's (MRK) Keytruda for a new indication. FDA grants EUA to Roche's Actemra for COVID-19.
Exelixis (EXEL) Down on Data from Ongoing Liver Cancer Study
by Zacks Equity Research
Exelixis (EXEL) and partner announce unimpressive data from the late-stage COSMIC-312 study in patients with previously untreated advanced hepatocellular carcinoma.
BioMarin (BMRN) Re-Files MAA for Hemophilia Gene Therapy in EU
by Zacks Equity Research
Biomarin Pharmaceutical's (BMRN) new MAA in EU includes 52 weeks' data from the phase III GENEr8-1 study, along with four and three-year follow-up data from the ongoing phase I/II dose escalation study.
Roche's (RHHBY) Actemra Gets FDA Emergency Nod for COVID-19
by Zacks Equity Research
The FDA issues an Emergency Use Authorization for Roche's (RHHBY) Actemra for the treatment of COVID-19 in hospitalized adults and pediatric patients.